|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US20040121370A1
(en)
|
2002-09-11 |
2004-06-24 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
|
WO2005035575A2
(en)
|
2003-08-22 |
2005-04-21 |
Medimmune, Inc. |
Humanization of antibodies
|
|
EP3214095B1
(en)
|
2005-05-12 |
2019-12-11 |
ZymoGenetics, Inc. |
Compositions and methods for modulating immune responses
|
|
WO2007141274A2
(en)
|
2006-06-06 |
2007-12-13 |
Crucell Holland B.V. |
Human binding molecules having killing activity against staphylococci and uses thereof
|
|
EP3208612B1
(en)
|
2008-04-09 |
2019-09-18 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
CA3083324A1
(en)
|
2010-03-05 |
2011-09-09 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
WO2013160396A1
(en)
|
2012-04-26 |
2013-10-31 |
Boehringer Ingelheim International Gmbh |
Combination of cd37 antibodies with bendamustine
|
|
US9090694B2
(en)
*
|
2012-04-30 |
2015-07-28 |
Janssen Biotech, Inc. |
ST2L antibody antagonists
|
|
MX2014014951A
(es)
|
2012-06-06 |
2015-03-13 |
Oncomed Pharm Inc |
Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
|
|
CN105102480B
(zh)
|
2012-12-24 |
2019-04-16 |
艾伯维公司 |
催乳素受体结合蛋白及其用途
|
|
CA2916681A1
(en)
|
2013-07-16 |
2015-01-22 |
Genentech, Inc. |
Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
|
|
PL3036258T3
(pl)
|
2013-08-22 |
2023-12-11 |
The Council Of The Queensland Institute Of Medical Research |
Modulowanie receptora dla leczenia raka i infekcji wirusowych
|
|
WO2015035112A1
(en)
|
2013-09-05 |
2015-03-12 |
The Johns Hopkins University |
Cancer therapy via a combination of epigenetic modulation and immune modulation
|
|
CA2922950A1
(en)
*
|
2013-09-30 |
2015-04-02 |
Shinya Ishii |
Method for producing antigen-binding molecule using modified helper phage
|
|
AU2015228372B2
(en)
|
2014-03-12 |
2018-05-31 |
Yeda Research And Development Co. Ltd |
Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
|
|
WO2015143343A2
(en)
|
2014-03-21 |
2015-09-24 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
|
|
EP3144388B1
(en)
|
2014-05-13 |
2020-07-01 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirecting antigen-binding molecule for cells having immunosuppression function
|
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
|
SG11201700258VA
(en)
|
2014-07-16 |
2017-02-27 |
Genentech Inc |
Methods of treating cancer using tigit inhibitors and anti-cancer agents
|
|
AU2015305754B2
(en)
|
2014-08-19 |
2018-10-25 |
Merck Sharp & Dohme Llc |
Anti-tigit antibodies
|
|
TWI716362B
(zh)
|
2014-10-14 |
2021-01-21 |
瑞士商諾華公司 |
針對ｐｄ－ｌ１之抗體分子及其用途
|
|
BR112017008399A2
(pt)
|
2014-10-24 |
2018-06-19 |
StemImmune, Incorporated |
abordagem de imunoterapia de combinação para tratamento de câncer
|
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
|
CN107207594B
(zh)
|
2014-12-23 |
2019-05-07 |
百时美施贵宝公司 |
针对tigit的抗体
|
|
WO2016154544A1
(en)
|
2015-03-25 |
2016-09-29 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
WO2016180781A1
(en)
|
2015-05-08 |
2016-11-17 |
Michele Maio |
Combination therapy of mesothelioma
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
AU2016285920A1
(en)
|
2015-06-29 |
2018-02-01 |
Bristol-Myers Squibb Company |
Antibodies to CD40 with enhanced agonist activity
|
|
EP3328363A4
(en)
|
2015-07-31 |
2019-08-21 |
Tarveda Therapeutics, Inc. |
COMPOSITIONS AND METHOD FOR IMMUNOMODULATION
|
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
|
EP3334757A4
(en)
|
2015-08-14 |
2019-04-03 |
Merck Sharp & Dohme Corp. |
ANTI-Tigit ANTIBODY
|
|
CN114605548A
(zh)
|
2015-09-01 |
2022-06-10 |
艾吉纳斯公司 |
抗-pd-1抗体及其使用方法
|
|
CN108137691B
(zh)
|
2015-09-02 |
2021-10-19 |
耶路撒冷希伯来大学伊萨姆研究发展有限公司 |
特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
|
|
EP3349792A1
(en)
|
2015-09-14 |
2018-07-25 |
Compass Therapeutics LLC |
Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-
|
|
CA2994858C
(en)
*
|
2015-09-25 |
2024-01-23 |
Genentech, Inc. |
Anti-tigit antibodies and methods of use
|
|
PL3356413T3
(pl)
|
2015-10-01 |
2022-04-19 |
Potenza Therapeutics, Inc. |
Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania
|
|
CN108136010A
(zh)
|
2015-10-08 |
2018-06-08 |
宏观基因有限公司 |
用于治疗癌症的联合疗法
|
|
CN114181960B
(zh)
|
2015-10-09 |
2024-08-23 |
美天施生物科技有限公司 |
嵌合抗原受体和使用方法
|
|
EP3402517B1
(en)
|
2016-01-15 |
2025-08-20 |
RFEMB Holdings, LLC |
Immunologic treatment of cancer by using a tumor ablation technic together with a combination of a ctla-4 inhibitor, a pd-1 inhibitor and gm-csf
|
|
WO2017152088A1
(en)
|
2016-03-04 |
2017-09-08 |
JN Biosciences, LLC |
Antibodies to tigit
|
|
WO2017218970A1
(en)
|
2016-06-17 |
2017-12-21 |
Varian Medical Systems, Inc. |
Immune modulators in combination with radiation treatment
|
|
US12257352B2
(en)
|
2016-06-20 |
2025-03-25 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
CN110088132B
(zh)
|
2016-08-17 |
2020-10-27 |
康姆普根有限公司 |
抗tigit抗体，抗pvrig抗体及其组合
|
|
JP7200093B2
(ja)
|
2016-09-15 |
2023-01-06 |
アイデラ・ファーマシューティカルズ，インコーポレーテッド |
がん治療用ｔｌｒ９アゴニストを用いた免疫調節
|
|
CN110662552A
(zh)
|
2016-11-30 |
2020-01-07 |
昂科梅德制药有限公司 |
包含tigit结合剂的癌症治疗方法
|
|
US10759855B2
(en)
|
2016-12-02 |
2020-09-01 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to TIGIT
|
|
CN109071656B
(zh)
|
2017-01-05 |
2021-05-18 |
璟尚生物制药公司 |
检查点调节物拮抗剂
|
|
EP3589313A4
(en)
|
2017-02-28 |
2021-05-19 |
Seagen Inc. |
ANTI-TIGITE ANTIBODY
|
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
|
RS64576B1
(sr)
|
2017-05-01 |
2023-10-31 |
Agenus Inc |
Anti-tigit antitela i postupci njihove primene
|
|
JP7402693B2
(ja)
|
2017-05-02 |
2023-12-21 |
メルク・シャープ・アンド・ドーム・エルエルシー |
単独のおよびプログラム死受容体１（ｐｄ－１）抗体と組み合わされた抗ｔｉｇｉｔ抗体の安定な製剤、ならびにその使用方法
|
|
WO2018229163A1
(en)
|
2017-06-14 |
2018-12-20 |
King's College London |
Methods of activating v delta 2 negative gamma delta t cells
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
IL272227B2
(en)
|
2017-07-27 |
2025-09-01 |
iTeos Belgium SA |
Anti-tigit antibodies
|
|
CN111655286A
(zh)
|
2017-08-11 |
2020-09-11 |
布林克生物医学简易股份公司 |
作为免疫调节剂的cd96结合剂
|
|
US11512129B2
(en)
|
2017-09-29 |
2022-11-29 |
Jiangsu Hengrui Medicine Co., Ltd. |
TIGIT antibody, antigen-binding fragment thereof, and medical use thereof
|
|
WO2019091449A1
(zh)
|
2017-11-10 |
2019-05-16 |
江苏恒瑞医药股份有限公司 |
Cd96抗体、其抗原结合片段及医药用途
|
|
TW201930358A
(zh)
|
2017-12-28 |
2019-08-01 |
大陸商南京傳奇生物科技有限公司 |
針對ｔｉｇｉｔ之單域抗體及其變異體
|
|
TWI816729B
(zh)
*
|
2017-12-30 |
2023-10-01 |
英屬開曼群島商百濟神州有限公司 |
抗tigit抗體及其作為治療和診斷的用途
|
|
KR20200109313A
(ko)
|
2018-01-15 |
2020-09-22 |
난징 레전드 바이오테크 씨오., 엘티디. |
Tigit에 대한 항체 및 이의 변이체
|
|
WO2019152574A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
|
|
CA3086936C
(en)
|
2018-02-06 |
2022-11-29 |
I-Mab Biopharma Us Limited |
Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
|
|
CN111836831A
(zh)
|
2018-02-26 |
2020-10-27 |
豪夫迈·罗氏有限公司 |
用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
|
|
MX2020008795A
(es)
|
2018-02-28 |
2020-10-08 |
Yuhan Corp |
Anti cuerpos anti tigit y usos de los mismos.
|
|
JP2021534196A
(ja)
|
2018-08-23 |
2021-12-09 |
シージェン インコーポレイテッド |
抗ｔｉｇｉｔ抗体
|
|
EA202191176A1
(ru)
*
|
2018-10-31 |
2021-07-28 |
Делиниа, Инк. |
Поливалентные модуляторы регуляторных т-клеток
|
|
AR117327A1
(es)
*
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
|
EP3938396A1
(en)
*
|
2019-03-11 |
2022-01-19 |
Jounce Therapeutics, Inc. |
Anti-icos antibodies for the treatment of cancer
|
|
TWI760751B
(zh)
|
2019-05-29 |
2022-04-11 |
美商美國禮來大藥廠 |
Tigit及pd-1/tigit-結合分子
|
|
CA3285695A1
(en)
*
|
2019-06-26 |
2026-03-02 |
Ap Biosciences, Inc. |
Antibodies for t-cell activation
|
|
TW202122420A
(zh)
|
2019-08-30 |
2021-06-16 |
美商艾吉納斯公司 |
抗ｃｄ９６抗體及其使用方法
|
|
AR125753A1
(es)
|
2021-05-04 |
2023-08-09 |
Agenus Inc |
Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
|
|
CN117241827A
(zh)
*
|
2021-05-04 |
2023-12-15 |
艾吉纳斯公司 |
抗tigit抗体及其使用方法
|